The unit Clinical Pharmacology and Pharmacotherapy and the Healthcare Management Centre at Vlerick Business School is looking for a PhD researcher to investigate how patient access to innovative medicines can be facilitated.
We are a vibrant unit at the Department of Pharmaceutical and Pharmacological Sciences with a motivated team of researchers involved in several projects on both regulatory and market access level.
This project will give you the opportunity to engage with both KU Leuven and Vlerick researchers and to collaborate with several external partners such as representatives from the government agencies and pharmaceutical industry.
Master in pharmaceutical sciences, master in drug development, master in biomedical sciences, master in medicine, master in bioengineering, master in law, master in bioethics, or master in social sciences with outspoken interest in market access, regulatory sciences and health economics.
Candidates with a Master’s degree in another field may apply if they can demonstrate their expertise and interest in market access of medicines.
You will engage yourself with enthusiasm and perseverance to a four-year research project.
You are ambitious, dynamic, flexible and take an open attitude towards problems and evolutions.
You are directed towards innovation, including health economics and patient access.
You are able to work independently and take decisions.
You have excellent social and communication skills to deal with all stakeholders in this field. You are able to work in an international multidisciplinary team and cooperate with other team members.
You can speak fluently Dutch (French is a plus) and have good written and oral knowledge of English.
You have good didactic skills and you can coach and motivate other persons.
Drug development today is increasingly focused on the development of biological products, including advanced therapy medicinal products (ATMPs).
However, market uptake of these therapies has been limited in Europe due to difficulties in obtaining reimbursement. Governments experience decision-uncertainty due to persisting uncertainties caused by shortcomings in clinical trial design and the unavailability of long-term data on efficacy and safety.
Furthermore, the sustainability of the healthcare budget is threatened by having to absorb potential peaks of treatment prices of €320,000 for CAR-Tcell therapies up to €1,900,000 for gene therapy treating spinal muscular atrophy.
The selected PhD student will contribute to developing new methods to facilitate the reimbursement of innovative therapies and subsequently aid patients in gaining access to these transformative therapies.
This research project will aim to tackle the most important challenges that ATMPs face when trying to obtain market access :
The PhD project will require a highly collaborative approach to formulate solutions acceptable to all relevant stakeholders.
Therefore, the PhD student will have to build durable relationships with governmental agencies, pharmaceutical industry, patient organisations and healthcare providers.
The research will include quantitative studies (literature reviews, surveys, analysis of data) and qualitative studies (semi-structure dinterviews, focus group discussions, expert panels, workshops).
Description of function
This research has the intention to lead to a PhD degree.